Ociperlimab, CAS 2342597-93-5

Product Description: Ociperlimab is a humanized IgG1 anti-TIGIT antibody. Ociperlimab binds to the extracellular domain of human TIGIT with high affinity (KD = 0.135 nM). Ociperlimab blocks the interaction between TIGIT and its ligands PVR or PVR-L2. Ociperlimab can be used in research of cancer[1][2].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Chen X, et, al. An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models. Front Immunol. 2022 Feb 22;13:828319./[2]Zhu J, et, al. Immune Checkpoints and targeted agents in relapse and graft-versus-host disease after hematopoietic stem cell transplantation. Mol Biol Rep. 2022 Dec 26.

CAS Number: 2342597-93-5

Molecular Weight: N/A

Compound Purity: 98.14

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: Others

• Artikelnummer: MEXHY-P99763-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99763-5
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated